SmallCapPower | April 4, 2016: Earnings increases is one of the most important factors in determining a company’s ability to outperform an index, such as the S&P 500. To that end, it all starts with revenue growth and, most importantly, sustainable revenue growth. That being said, the companies on our list today have grown its overall revenue, consistently, during the past four quarters.
OPKO Health Inc. (NYSE: OPK) – $10.41
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company that is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.
- Market Cap: $1,790,728,391
- Revenue (LTM): $491,738,000
- Operating Income (LTM): -$98,480,000
- Q/Q growth (last quarter): 981.7%
Dollar Tree Inc. (NASDAQ: DLTR) – $83.31
Dollar Tree, Inc. (Dollar Tree) is an operator of discount variety stores offering merchandise at the fixed price of $1.00. The Company offers a selection of everyday basic products and also supplements these basic, everyday items with seasonal, closeout and promotional merchandise. As of July 06, 2015, the Company operated more than 13,600 stores across 48 states and five Canadian provinces. Its stores operate under the brands of Dollar Tree, Dollar Tree Canada, Deals and Family Dollar.
- Market Cap: $19,567,203,302
- Revenue (LTM): $15,498,400,000
- Operating Income (LTM): $1,049,700,000
- Q/Q growth (last quarter): 116.7%
Albemarle Corp. (NYSE: ALB) – $65.20
Albemarle Corporation (Albemarle) is a developer, manufacturer and marketer of specialty chemicals across a range of end markets, including the petroleum refining, consumer electronics, plastics/packaging, construction, automotive, lubricants, pharmaceuticals, crop protection, food-safety and custom chemistry services markets. The Company operates through two segments: Performance Chemicals and Catalyst Solutions.
- Market Cap: $7,185,875,432
- Revenue (LTM): $3,651,335,000
- Operating Income (LTM): $442,435,000
- Q/Q growth (last quarter): 55.4%
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) – $405.25
Biotechnology & Medical Research
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use.
- Market Cap: $37,690,199,994
- Revenue (LTM): $4,103,728,000
- Operating Income (LTM): $1,233,055,000
- Q/Q growth (last quarter): 36.9%
Walgreens Boots Alliance Inc. (NASDAQ: WBA) – $86.70
Walgreens Boots Alliance, Inc. (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led health and wellbeing enterprise that operates through three segments: Retail Pharmacy USA, which consists of the Walgreens business, including the operation of retail drugstores and convenient care clinics, in addition to providing specialty pharmacy services; Retail Pharmacy International, which consists of the Alliance Boots pharmacy-led health and beauty stores, optical practices and related contract manufacturing operations, and Pharmaceutical Wholesale, which consists of the Alliance Boots pharmaceutical wholesaling and distribution businesses. Its portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare.
- Market Cap (mm): $90,215,600,822
- Revenue (LTM): $112,923,000,000
- Operating Income (LTM): $5,082,000,000
- Q/Q growth (last quarter): 48.5%